Replies to post #81637 on Biotech Values

[mcbio]

Arzerra vs. RIGL's R788 in RA

Note that RIGL's R788 showed better efficacy results in a similar trial (methotrexate failures studied for 6 months of treatment). See: http://ir.rigel.com/phoenix.zhtml?c=120936&p=irol-newsArticle&ID=1305912&highlight=

In particular, R788 had an ACR20 response rate of 66% (p<0.001) at the 100mg bid dose (primary dose being carried forward) at 6 months compared to Arzerra's ACR20 score of 50%. Note that this data comes from RIGL's TASKi2 study, which was a success, not the "incongruent" TASKi3 study comprised of biologic failures. Arzerra may have a better safety profile although it's not oral, like R788.

[masterlongevity]

rituxan had a great run. not quite over, but 13 yrs of no competition is pretty impressive